Werewolf Therapeutics (HOWL) Return on Equity (2021 - 2025)
Werewolf Therapeutics (HOWL) has disclosed Return on Equity for 5 consecutive years, with 2.05% as the latest value for Q3 2025.
- On a quarterly basis, Return on Equity fell 142.0% to 2.05% in Q3 2025 year-over-year; TTM through Sep 2025 was 2.05%, a 142.0% decrease, with the full-year FY2024 number at 0.77%, down 46.0% from a year prior.
- Return on Equity was 2.05% for Q3 2025 at Werewolf Therapeutics, down from 1.48% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.3% in Q4 2023 to a low of 2.05% in Q3 2025.
- A 5-year average of 0.65% and a median of 0.44% in 2022 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: rose 15bps in 2023, then plummeted -142bps in 2025.
- Werewolf Therapeutics' Return on Equity stood at 0.31% in 2021, then plummeted by -38bps to 0.43% in 2022, then rose by 29bps to 0.3% in 2023, then tumbled by -189bps to 0.88% in 2024, then crashed by -133bps to 2.05% in 2025.
- Per Business Quant, the three most recent readings for HOWL's Return on Equity are 2.05% (Q3 2025), 1.48% (Q2 2025), and 1.13% (Q1 2025).